Literature DB >> 3387716

Optimal two-stage designs for clinical trials with binary response.

P F Thall1, R Simon, S S Ellenberg, R Shrager.   

Abstract

We present a simple two-stage design for a randomized clinical trial with dichotomous outcomes. It is based on a design of Ellenberg and Eisenberger which permits early acceptance of the null hypothesis after the first stage. We have optimized the design by minimizing the average expected sample size subject to constraints on the type 1 and type 2 errors. The resulting designs have maximum sample size only slightly larger than that of single stage trial, with 40-45 per cent of this maximum allocated to the first stage, and null hypothesis probability of early acceptance in excess of 0.60.

Mesh:

Year:  1988        PMID: 3387716     DOI: 10.1002/sim.4780070504

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  9 in total

Review 1.  A review of phase 2-3 clinical trial designs.

Authors:  Peter F Thall
Journal:  Lifetime Data Anal       Date:  2007-09-02       Impact factor: 1.588

2.  Innovative Clinical Trial Designs: Toward a 21st-Century Health Care System.

Authors:  Tze L Lai; Philip W Lavori
Journal:  Stat Biosci       Date:  2011-12

3.  Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.

Authors:  Sarit E Assouline; Torsten Holm Nielsen; Stephen Yu; Miguel Alcaide; Lauren Chong; David MacDonald; Axel Tosikyan; Vishal Kukreti; Abbas Kezouh; Tina Petrogiannis-Haliotis; Marco Albuquerque; Daniel Fornika; Sepideh Alamouti; Remi Froment; Celia M T Greenwood; Kathleen Klein Oros; Errol Camglioglu; Ayushi Sharma; Rosa Christodoulopoulos; Caroline Rousseau; Nathalie Johnson; Michael Crump; Ryan D Morin; Koren K Mann
Journal:  Blood       Date:  2016-05-10       Impact factor: 22.113

Review 4.  Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology.

Authors:  Mei-Yin C Polley; Ying Kuen Cheung
Journal:  JCO Precis Oncol       Date:  2019-10-24

5.  Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.

Authors:  W K Alfred Yung; James J Vredenburgh; Timothy F Cloughesy; Phioanh Nghiemphu; Barbara Klencke; Mark R Gilbert; David A Reardon; Michael D Prados
Journal:  Neuro Oncol       Date:  2010-07-08       Impact factor: 12.300

Review 6.  Integrated phase II/III clinical trials in oncology: a case study.

Authors:  Meihua Wang; James J Dignam; Qiang E Zhang; John F DeGroot; Minesh P Mehta; Sally Hunsberger
Journal:  Clin Trials       Date:  2012-11-22       Impact factor: 2.486

7.  Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.

Authors:  P Comella; G Frasci; G De Cataldis; N Panza; R Cioffi; C Curcio; M Belli; A Bianco; G Ianniello; L Maiorino; M Della Vittoria; J Perchard; G Comella
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

Review 8.  Basic design considerations for clinical trials in oncology.

Authors:  S Piantadosi; N Saijo; T Tamura
Journal:  Jpn J Cancer Res       Date:  1992-06

9.  Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.

Authors:  Emil Lou; Katherine B Peters; Ashley L Sumrall; Annick Desjardins; David A Reardon; Eric S Lipp; James E Herndon; April Coan; Leighann Bailey; Scott Turner; Henry S Friedman; James J Vredenburgh
Journal:  Cancer Med       Date:  2013-01-24       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.